Clinical Trials Directory

Trials / Completed

CompletedNCT05497765

An Intervention Study of Compound Silymarin in Patients With Non-alcoholic Fatty Liver Disease

Effects of Compound Silymarin on Biomarkers of Lipid Metabolism and Inflammation in Patients With Non-alcoholic Fatty Liver Disease: A Randomized Controlled Double-blind Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
94 (actual)
Sponsor
Guangzhou Medical University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China. The aim of this project is to evaluate the effects of compound silymarin on biomarkers of lipid metabolism and inflammation in the patients with NAFLD.

Detailed description

Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China but still has no exact therapy for this disease instead of improving our diet and enhancing physical activity. Silymarin is a mixture of flavonoids extracted from seeds of Silybum marianum or milk thistle, and its major active compound is silibinin. Because of its antioxidant, anti-inflammatory and antifibrotic power, silymarin has important biological effects in NAFLD. Furthermore, some traditional liver protective Chinese medicines are also helpful in controlling the progression of NAFLD, such as pueraria, schisandra and salvia miltiorrhiza. At present, there are few reports on the combination of silymarin and these traditional Chinese medicines in the treatment of NAFLD. This study aims to test the effect of compound silymarin on laboratory markers and clinical evolution of patients with NAFLD.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTSilibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhizaTake 4 tablets with warm water twice a day
DIETARY_SUPPLEMENTSilibinin extractTake 4 tablets with warm water twice a day
DIETARY_SUPPLEMENTPlaceboTake 4 tablets with warm water twice a day

Timeline

Start date
2022-08-01
Primary completion
2024-01-31
Completion
2024-02-20
First posted
2022-08-11
Last updated
2024-02-28

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05497765. Inclusion in this directory is not an endorsement.